SCHEMBL4834273

SCHEMBL4834273

CCC(CC)(c1ccc(NC(=O)C=Cc2snnc2-c2ccc(F)cc2)cc1)P(=O)(O)O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.41
SNCA P37840 2/20 0.40
TDP1 Q9NUW8 4/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
MMP1 P03956 4/20 0.37
MMP2 P08253 4/20 0.37
MMP9 P14780 4/20 0.37
EGFR P00533 1/20 0.37
PTPN1 P18031 1/20 0.36
RAB9A P51151 6/20 0.35
NPC1 O15118 5/20 0.35
TP53 P04637 3/20 0.35
POLB P06746 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
LMNA P02545 1/20 0.34
MAPK1 P28482 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
KDM4E B2RXH2 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834255 1.00 MAOB (0.41) MAOBSNCATDP1MEN1KMT2A
SCHEMBL4831227 0.88 MAOB (0.43) MAOBSNCATDP1MEN1KMT2A
SCHEMBL4831239 0.88 MAOB (0.43) MAOBSNCATDP1MEN1KMT2A
SCHEMBL27612956 0.87 MAOB (0.44) MAOBSNCATDP1MEN1KMT2A
SCHEMBL4827021 0.85 MAOB (0.41) MAOBSNCATDP1MEN1KMT2A
SCHEMBL4827004 0.85 MAOB (0.41) MAOBSNCATDP1MEN1KMT2A
SCHEMBL4834235 0.82 SNCA (0.41) MAOBSNCATDP1MEN1KMT2A
SCHEMBL4834217 0.82 SNCA (0.41) MAOBSNCATDP1MEN1KMT2A
SCHEMBL4834265 0.80 BTK (0.40) SNCATDP1MEN1KMT2AMMP1
SCHEMBL4829169 0.79 HDAC1 (0.43) MAOBMEN1KMT2ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287438-A1 Agent for preventing or treating neuropathy MOMOSE YU 2008-11-20 US disclosed
US-7423159-B2 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-09-09 US disclosed
US-20060004069-A1 Agent for preventing or treating neuropathy TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-01-05 US disclosed
EP-1556032-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY Takeda Pharmaceutical Company Limited (JP) 2005-07-27 EP disclosed
WO-2004039365-A1 AGENT FOR PREVENTING OR TREATING NEUROPATHY TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004069-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 MAOB 881/4885SNCA 1545/4885TDP1 3636/4885
US-20080287438-A1 Agent for preventing or treating neuropathy NR2C2, NR0B2, NR2E1 MAOB 881/4885SNCA 1545/4885TDP1 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.